FDA approves first-in-class bispecific for multiple myeloma

被引：1

|

作者：

不详

机构：

来源：

NATURE BIOTECHNOLOGY | 2023年 / 41卷 / 09期

关键词：

D O I：

10.1038/s41587-023-01962-x

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：1181 / 1181

页数：1

相关论文

共 50 条

[1] FDA approves first-in-class bispecific for multiple myeloma
[J]. Nature Biotechnology, 2023, 41 : 1180 - 1180
[2] FDA approves first-in-class AKT inhibitor
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2024, 23 : 9 - 9
[3] FDA approves first-in-class osteoporosis drug
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (06) : 411 - 411
[4] FDA approves first-in-class osteoporosis drug
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2019, 18 (6) : 411 - 411
[5] FDA approves first-in-class AKT inhibitor
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (01) : 9 - 9
[6] FDA approves first-in-class SYK inhibitor
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (06) : 385 - 385
[7] FDA approves first-in-class SYK inhibitor
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2018, 17 : 385 - 385
[8] FDA approves first-in-class cancer metabolism drug
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2017, 16 : 593 - 593
[9] FDA approves first-in-class cancer metabolism drug
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (09) : 593 - 593
[10] FDA approves first-in-class HIV capsid inhibitor
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2023, 22 : 90 - 90

← 1 2 3 4 5 →